Author: Huarte, Eduardo; Peel, Michael T.; Verbist, Katherine; Fay, Brittany L.; Bassett, Rachel; Albeituni, Sabrin; Nichols, Kim E.; Smith, Paul A.
Title: Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome Cord-id: ngzwm7sp Document date: 2021_4_22
ID: ngzwm7sp
Snippet: Hyperinflammatory syndromes comprise a heterogeneous group of disorders characterized by severe inflammation, multiple organ dysfunction, and potentially death. In response to antigenic stimulus (e.g., SARS-CoV-2 infection), overactivated CD8+ T-cells and macrophages produce high levels of proinflammatory cytokines, such as IFN-γ, TNF-α, IL-6, and IL-12. Multiple inflammatory mediators implicated in hyperinflammatory syndromes utilize the Janus kinase–signal transducers and activators of tra
Document: Hyperinflammatory syndromes comprise a heterogeneous group of disorders characterized by severe inflammation, multiple organ dysfunction, and potentially death. In response to antigenic stimulus (e.g., SARS-CoV-2 infection), overactivated CD8+ T-cells and macrophages produce high levels of proinflammatory cytokines, such as IFN-γ, TNF-α, IL-6, and IL-12. Multiple inflammatory mediators implicated in hyperinflammatory syndromes utilize the Janus kinase–signal transducers and activators of transcription (JAK-STAT) cascade to propagate their biological function. Our findings demonstrate that oral ruxolitinib dosing designed to mimic clinically relevant JAK-STAT pathway inhibition significantly reduces the harmful consequences of immune overactivation in multiple hyperinflammatory models. In contrast to monoclonal antibody therapies targeting a single cytokine, ruxolitinib effectively downregulates the functional effect of multiple cytokines implicated in hyperinflammatory states, without broad immunosuppression.
Search related documents:
Co phrase search for related documents- acute ards respiratory distress syndrome and lps stimulation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute ards respiratory distress syndrome and mab monoclonal antibody: 1, 2
- acute ards respiratory distress syndrome and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- acute ards respiratory distress syndrome and macrophage activation syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- lps challenge and macrophage cytokine production inhibition: 1
- lps injection and macrophage activation: 1
- lps stimulation and macrophage activation: 1, 2
- lps stimulation and macrophage activation syndrome: 1
Co phrase search for related documents, hyperlinks ordered by date